Usted buscó: neuronopathic (Inglés - Maltés)

there is no information on the effect of cerezyme on brain-based symptoms of patients with chronic neuronopathic gaucher disease.
m’ hemm l- ebda tagħrif dwar l- effett ta ’ cerezyme fuq sintomi li huma bbażati fuq il- moħħ ta ’ pazjenti li jbatu mill- marda kronika newronopatika ta 'gaucher.

medical or healthcare professionals are encouraged to register gaucher patients, including those with chronic neuronopathic manifestations of the disease, in the “icgg gaucher registry”.
professjonisti mediċi u tal-kura tas-saħħa huma mħeġġa jirreġistraw il-pazjenti gaucher, inklużi dawk li għandhom sinjali kroniċi u newropatiċi tal-marda fir-reġistru ta’ l-icgg gaucher.

the efficacy of cerezyme on neurological symptoms of chronic neuronopathic gaucher patients has not been established and no special dosage regimen can be recommended for these manifestations (see section 5.1).
l-effikaċja ta’ cerezyme fuq is-sintomi newroloġikali ta’ pazjenti li jbatu bil-marda kronika u newronopatika tal-gaucher ma ġietx stabbilita u ma jista’ jiġi rrakkomandat l-ebda reġimen speċjali ta’ dożaġġ għal dawn il-manifestazzjonijiet (ara sezzjoni 5.1).

cerezyme is used in patients who have type 1 (non-neuronopathic) or type 3 (chronic neuronopathic) gaucher disease and who have one or more of the following conditions caused by the disease: • anaemia (low red blood cell counts), • thrombocytopenia (a decrease in the number of platelets in the blood), • bone disease, • hepatomegaly (enlarged liver) or splenomegaly (enlarged spleen).
cerezyme jintuża f’ pazjenti li għandhom il- marda ta ’ gaucher ta ’ tip 1 (mhux- newronopatika) jew ta ’ tip 3 (newronopatika kronika) u li kellhom kundizzjoni waħda jew aktar minn dawn li ġejjin ikkawżati mill- marda: • anemija (għadd ta ’ ċelloli tad- demm ħomor baxx), • tromboċitopenja (tnaqqis fin- numru ta ’ plejtlits fid- demm), • marda fl- għadam, • epatomegalija (fwied imkabbar) jew splenomegalija (milsa mkabbra).